- Home
- RANI vs KZR Comparison
RANI vs KZR Comparison
Compare RANI & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RANI
- KZR
- Stock Information
- Founded
- RANI 2012
- KZR 2015
- Country
- RANI United States
- KZR United States
- Employees
- RANI N/A
- KZR N/A
- Industry
- RANI Medicinal Chemicals and Botanical Products
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- RANI Health Care
- KZR Health Care
- Exchange
- RANI Nasdaq
- KZR Nasdaq
- Market Cap
- RANI 41.6M
- KZR 46.5M
- IPO Year
- RANI 2021
- KZR 2018
- Fundamental
- Price
- RANI $1.31
- KZR $6.19
- Analyst Decision
- RANI Strong Buy
- KZR Hold
- Analyst Count
- RANI 5
- KZR 2
- Target Price
- RANI $11.80
- KZR $9.00
- AVG Volume (30 Days)
- RANI 420.9K
- KZR 48.3K
- Earning Date
- RANI 11-14-2024
- KZR 03-13-2025
- Dividend Yield
- RANI N/A
- KZR N/A
- EPS Growth
- RANI N/A
- KZR N/A
- EPS
- RANI N/A
- KZR N/A
- Revenue
- RANI N/A
- KZR N/A
- Revenue This Year
- RANI N/A
- KZR N/A
- Revenue Next Year
- RANI N/A
- KZR N/A
- P/E Ratio
- RANI N/A
- KZR N/A
- Revenue Growth
- RANI N/A
- KZR N/A
- 52 Week Low
- RANI $1.24
- KZR $5.20
- 52 Week High
- RANI $8.75
- KZR $11.40
- Technical
- Relative Strength Index (RSI)
- RANI 35.89
- KZR 38.28
- Support Level
- RANI $1.24
- KZR $6.15
- Resistance Level
- RANI $1.61
- KZR $6.50
- Average True Range (ATR)
- RANI 0.11
- KZR 0.29
- MACD
- RANI 0.02
- KZR -0.02
- Stochastic Oscillator
- RANI 18.92
- KZR 5.13
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.